takeaway discuss manag
discuss potenti near-term impact manag
key takeaway commerci sale forc convers virtual format
enabl continu interact physician although anticip lower sale
product disrupt new patient flow far clinic trial
readout tezepelumab omecamtiv-mecarbil remain on-
track recent fda guidanc allow flexibl assess endpoint
manag prudent navig uncertainti view
financi well-posit recent publish forecast aimovig
tezepelumab omecamtiv-mecarbil believ provid long-term
revenu diversif base view impact lower sale
estim aimovig repatha enbrel otezla prolia result new
price target maintain outperform
sale forc convert virtual format respons pandem
manag expect minim disrupt howev note sever product
new prescript proport total assum disrupt
new patient start consequ lower sale estim
aimovig repatha enbrel otezla prolia forecast gener
consensu exhibit
clinic trial readout time remain on-track anticip flexibl base
fda guidanc believ major focu next updat
expect read summer base enrol complet
primari endpoint six-month orr view bar monotherapi
nsclc base docetaxel combin studi on-going
recent publish forecast tezepelumab omecamtiv-mecarbil
manag confirm trial remain on-track tezepelumab
forecast peak risk-adjust sale anticip pivot
direct trial adult uncontrolled/sever asthma readout
omecamtiv-mecarbil forecast peak risk-adjust sale
anticip galactic-hf cv-outcom studi data
manag execut prudenc provid transpar drug suppli
expect shortag financi well-posit withstand
prolong pandem cash balanc estim
believ ig-rat debt provid reason
leverag debt/ev interest coverag ratio exhibit
view current share price attract entri point ytd
vs nbi note dividend yield provid
attract yield updat sale estim drive new pt exhibit
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
year price histori
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel stabl
next year margin expand manag
track record financi disciplin top line believ
posit maintain long-term revenu stabil
matur product declin new product continu grow
pipelin deliv steadi flow new product
offer dividend yield believ provid valuat
updat data kra inhibitor major
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top-lin essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit oppenheim vs consensu estim repatha annual sale
exhibit oppenheim vs consensu estim aimovig annual sale
exhibit oppenheim vs consensu estim annual total revenu
exhibit believ financi well-posit withstand prolong pandem cash
balanc estim believ ig-rat
debt provid reason leverag debt/ev interest coverag ratio
compar favor compani debt capit within coverag
exhibit total revenu forecast breakdown product segment
coverag ratiotot debt percent enterpris revenu estim pipelinehpt secondari ckdprimari caredenosumaboncologyauto-immunegrowth factorsoth outperform
exhibit sotp analysi valu primari repatha aimovig pipelin valu
tezepelumab omecamtiv-mecarbil
exhibit dcf valuat support
drug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successprob-adjust npv mm sotp p-adj valu sharegrowth hpt secondari invest bgne equiti share outstand use valuat analysi except per-shar data revenu incom chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate inc
net incom equiti invest bgne
stock price compani mention report
compani lly-nys cover
